Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 62.9%

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 9,600 shares, a decline of 62.9% from the April 30th total of 25,900 shares. Based on an average daily trading volume, of 310,400 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Astellas Pharma Price Performance

Shares of ALPMY stock traded up $0.10 during mid-day trading on Friday, reaching $9.80. The company's stock had a trading volume of 175,835 shares, compared to its average volume of 204,115. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The firm's 50-day moving average is $9.53 and its two-hundred day moving average is $9.75. Astellas Pharma has a 1-year low of $8.37 and a 1-year high of $13.14. The company has a market cap of $17.73 billion, a P/E ratio of -44.52 and a beta of 0.27.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.02 billion. On average, research analysts predict that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.